Angie Baczyk serves as a Senior Human Resources Business Partner at Legend Biotech, a leading global biopharmaceutical company dedicated to innovating cell therapies for life-threatening diseases, particularly in the oncology space. With over 15 years of comprehensive experience across all HR functions, Angie plays a...
Angie Baczyk serves as a Senior Human Resources Business Partner at Legend Biotech, a leading global biopharmaceutical company dedicated to innovating cell therapies for life-threatening diseases, particularly in the oncology space. With over 15 years of comprehensive experience across all HR functions, Angie plays a pivotal role in shaping the people strategy that underpins the organization’s mission to deliver groundbreaking therapies. Reporting directly to the Head of HR, she is responsible for overseeing all aspects of human resources for commercial, scientific, and corporate functions in the United States, ensuring alignment with the company’s strategic objectives.
In her current role, Angie is instrumental in driving organizational effectiveness and fostering a culture of continuous improvement. She leads key projects focused on talent acquisition, leadership development, and employee engagement, leveraging her expertise in change management to navigate the complexities of a rapidly evolving industry. Her strategic approach to human capital management enables her to effectively advise C-level executives on HR policies and practices that enhance employee relations and promote a high-performance culture.
Angie’s skills in training and development are particularly critical as she implements programs designed to cultivate talent and support career growth within the organization. By utilizing applicant tracking systems and data-driven insights, she ensures that the recruitment process is efficient and aligned with the company’s diversity and inclusion goals. Her commitment to nurturing a supportive work environment not only enhances employee satisfaction but also drives the overall success of Legend Biotech in its quest to revolutionize cancer treatment.
